Abstract
Pseudomonas aeruginosa and Acinetobacter baumannii are two of the main bacteria responsible for nosocomial infections; both organisms are resistant to several classes of antibiotics making their infections very difficult to treat. Moreover, they possess a remarkable ability to form biofilms, which further enhances their antimicrobial resistance. Both organisms coordinate their formation of biofilms and their expression of virulence factors through quorum sensing, a system that regulates gene expression at high cell densities and that plays a key role in the establishment of bacterial infections. Hence, interfering with these quorum-sensing systems has been proposed as an alternative to traditional antibiotics for the eradication of bacterial infections. In this review, we describe the quorum sensing systems of both organisms, the way they coordinate the formation of biofilms, the recent advances in biofilm disruption by quorum sensing interference, and the advantages and limitations of the implementation of these novel therapeutic options in the clinic.
Keywords: Quorum quenching, Homoserine lactone, In vivo biofilm models, Stress response, Resistance.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Exploiting Quorum Sensing Inhibition for the Control of Pseudomonas aeruginosa and Acinetobacter baumannii Biofilms
Volume: 17 Issue: 17
Author(s): Israel Castillo-Juarez, Luis Esau Lopez-Jacome, Gloria Soberon-Chavez, Maria Tomas, Jintae Lee, Paulina Castaneda-Tamez, Ivan Angelo Hernandez-Barragan, Martha Yumiko Cruz-Muniz, Toshinari Maeda, Thomas K. Wood and Rodolfo Garcia-Contreras*
Affiliation:
- Department of Microbiology and Parasitology, Faculty of Medicine, UNAM, P.O. Box: 04890, Mexico City,Mexico
Keywords: Quorum quenching, Homoserine lactone, In vivo biofilm models, Stress response, Resistance.
Abstract: Pseudomonas aeruginosa and Acinetobacter baumannii are two of the main bacteria responsible for nosocomial infections; both organisms are resistant to several classes of antibiotics making their infections very difficult to treat. Moreover, they possess a remarkable ability to form biofilms, which further enhances their antimicrobial resistance. Both organisms coordinate their formation of biofilms and their expression of virulence factors through quorum sensing, a system that regulates gene expression at high cell densities and that plays a key role in the establishment of bacterial infections. Hence, interfering with these quorum-sensing systems has been proposed as an alternative to traditional antibiotics for the eradication of bacterial infections. In this review, we describe the quorum sensing systems of both organisms, the way they coordinate the formation of biofilms, the recent advances in biofilm disruption by quorum sensing interference, and the advantages and limitations of the implementation of these novel therapeutic options in the clinic.
Export Options
About this article
Cite this article as:
Castillo-Juarez Israel, Lopez-Jacome Esau Luis, Soberon-Chavez Gloria, Tomas Maria, Lee Jintae, Castaneda-Tamez Paulina, Hernandez-Barragan Angelo Ivan, Cruz-Muniz Yumiko Martha, Maeda Toshinari, Wood K. Thomas and Garcia-Contreras Rodolfo*, Exploiting Quorum Sensing Inhibition for the Control of Pseudomonas aeruginosa and Acinetobacter baumannii Biofilms, Current Topics in Medicinal Chemistry 2017; 17 (17) . https://dx.doi.org/10.2174/1568026617666170105144104
DOI https://dx.doi.org/10.2174/1568026617666170105144104 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Using PK/PD to Optimize Antibiotic Dosing for Critically Ill Patients
Current Pharmaceutical Biotechnology Comparative Biochemistry of GH3, GH20 and GH84 β-N-acetyl-Dhexosaminidases and Recent Progress in Selective Inhibitor Discovery
Current Drug Targets Recent Advances in Treatment Approaches of Mucopolysaccharidosis VI
Current Pharmaceutical Biotechnology Therapeutic Modulation of Gut Microbiota: Current Clinical Applications and Future Perspectives
Current Drug Targets Linezolid Activity Against Disseminated Listeria monocytogenes Meningitis and Central Nervous System Abscesses: Focus on Early Drug Myelotoxicity
Current Drug Safety Phage Therapy: A New Horizon in the Antibacterial Treatment of Oral Pathogens
Current Topics in Medicinal Chemistry Gene Cloning and Homology Modeling of the 3-Oxoacyl-ACP Synthase from Aeromonas hydrophila for Drug Discovery
Letters in Drug Design & Discovery Continuous Infusion of Antibiotics in Critically Ill Patients
Current Clinical Pharmacology Adenotonsillar Disease
Recent Patents on Inflammation & Allergy Drug Discovery Acute Tonsillitis
Infectious Disorders - Drug Targets Unique Applications of Novel Antifungal Drug Combinations
Anti-Infective Agents in Medicinal Chemistry New Developments in Antimicrobial Use in Sepsis
Current Pharmaceutical Design Torsades de Pointes in Patients with Polymyalgia Rheumatica
Current Pharmaceutical Design Radiolabeled Organism-Specific Antibodies for Diagnosis and Therapy of Infections
Current Medical Imaging Noncardiac Surgery: Evaluating and Minimizing Cardiac Risk
Current Cardiology Reviews The Evaluation and Management of Adult-Onset Henoch-Schonlein Purpura
Current Rheumatology Reviews Triple-Valve Endocarditis in a Diabetic Patient: Case Report and Literature Review
Current Cardiology Reviews Prevention of Microbial Communities: Novel Approaches Based Natural Products
Current Pharmaceutical Biotechnology Production and Application of Bacteriophage and Bacteriophage-Encoded Lysins
Recent Patents on Biotechnology Use of Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging in Drug Development for Ischemic Stroke
Current Drug Targets - CNS & Neurological Disorders